Tern

Terns Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate Updates

Retrieved on: 
Tuesday, November 14, 2023
JD, THR, Research, Safety, Chemistry, Acute leukemia, IND, PD, FXR, Clinical trial, SAD, Overweight, Fatty liver disease, Administration, Patient, DSM-IV codes, Tern, Week, Part, FDA, Obesity, Pharmacokinetics, BCR, Bangladesh Technical Education Board, Houston Methodist Hospital, Investigational New Drug, Non-alcoholic fatty liver disease, BCR-ABL, MD, CML, R, Research and development, NASH, DUET, Pharmaceutical industry, Medical imaging, Cryptocurrency

FOSTER CITY, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and non-alcoholic steatohepatitis (NASH), today reported financial results for the quarter ended September 30, 2023 and provided corporate updates.

Key Points: 
  • Based on its current operating plan, Terns expects these funds will be sufficient to support its planned operating expenses into 2026.
  • Research and Development (R&D) Expenses: R&D expenses were $14.8 million for the quarter ended September 30, 2023, as compared with $12.2 million for the quarter ended September 30, 2022.
  • General and Administrative (G&A) Expenses: G&A expenses were $18.4 million for the quarter ended September 30, 2023, as compared with $5.1 million for the quarter ended September 30, 2022.
  • Net Loss: Net loss was $29.8 million for the quarter ended September 30, 2023, as compared with $16.8 million for the quarter ended September 30, 2022.

Terns Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of TERN-601 Oral GLP-1 Receptor Agonist for Treatment of Obesity

Retrieved on: 
Thursday, November 2, 2023
DSM-IV codes, PD, BMI, Obesity, Tern, Weight loss, MD, MAD, SAD, Research, GIPR, Pharmacokinetics, NASH, PK, Fatty liver disease, Part, Body mass index, Safety, Overweight, Patient, Pharmaceutical industry

FOSTER CITY, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and non-alcoholic steatohepatitis (NASH), today announced that the first participant has been dosed in the Phase 1 clinical trial of TERN-601, the Company’s oral small-molecule glucagon-like peptide-1 receptor, or GLP-1R, agonist for the treatment of obesity.

Key Points: 
  • The Phase 1 trial is a randomized, double-blind, placebo-controlled single and multiple-ascending dose (SAD and MAD) trial to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of TERN-601 in healthy adults with obesity or overweight.
  • The starting TERN-601 dose is 30 mg, with subsequent dose levels based on review of emerging safety and PK data from prior cohorts.
  • Secondary endpoints include PK, efficacy as measured by body weight loss following 28-days of treatment with TERN-601, and other exploratory markers.
  • Top-line, proof of concept 28-day weight loss data from Part 2 (MAD) are expected in the second half of 2024.

Terns Pharmaceuticals Reports Second Quarter 2023 Financial Results and Corporate Updates

Retrieved on: 
Tuesday, August 8, 2023
FXR, Obesity, NASH, CML, Week, Cohort, GIPR, American Society of Clinical Oncology, Clinical trial, BCR-ABL, Research, Acute leukemia, THR, ASCO, DSM-IV codes, Administration, Team Impulse, DUET, American Diabetes Association, Fatty liver disease, Research and development, R, BMI, FDA, ADA, Society, Pharmaceutical industry, Cryptocurrency, Tern

FOSTER CITY, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, non-alcoholic steatohepatitis (NASH) and obesity, today reported financial results for the quarter ended June 30, 2023 and corporate updates.

Key Points: 
  • Based on its current operating plan, Terns expects these funds will be sufficient to support its planned operating expenses into 2026.
  • Research and Development (R&D) Expenses: R&D expenses were $14.2 million for the quarter ended June 30, 2023, as compared with $8.7 million for the quarter ended June 30, 2022.
  • General and Administrative (G&A) Expenses: G&A expenses were $7.0 million for the quarter ended June 30, 2023, as compared with $5.4 million for the quarter ended June 30, 2022.
  • Net Loss: Net loss was $17.9 million for the quarter ended June 30, 2023, as compared with $13.9 million for the quarter ended June 30, 2022.

Terns Pharmaceuticals Announces Leadership Transition

Retrieved on: 
Thursday, August 3, 2023
Initial public offering, Research and development, Obesity, NASH, Head, Senior advisor, Sen, Peritonitis, DSM-IV codes, Patient, Fatty liver disease, Pleasure, Health, Family, Pharmaceutical industry, Nursing, Tern

Mr. Sundaram also resigned from the Board of Directors of Terns but will remain on as a Senior Advisor to the Company.

Key Points: 
  • Mr. Sundaram also resigned from the Board of Directors of Terns but will remain on as a Senior Advisor to the Company.
  • Erin Quirk, M.D., President and Head of Research & Development at Terns, will assume leadership of the Company, effective immediately.
  • “On behalf of the entire Board, I extend our gratitude to Sen for his many contributions to Terns during his CEO tenure.
  • We wish all the best for Sen and his family and will always consider him a member of the Terns team,” said David Fellows, Chairman of the Board of Terns.

Terns Pharmaceuticals to Host Virtual Key Opinion Leader Event to Discuss TERN-701 and Advances in the Treatment Landscape for Chronic Myeloid Leukemia

Retrieved on: 
Tuesday, July 18, 2023
Fatty liver disease, Tern, Webcast, CML, Obesity, NASH, Acute leukemia, Pharmaceutical industry

FOSTER CITY, Calif., July 18, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, non-alcoholic steatohepatitis (NASH) and obesity, today announced it will host a virtual key opinion leader event to highlight the TERN-701 program and discuss advances in the treatment landscape for chronic myeloid leukemia (CML).

Key Points: 
  • FOSTER CITY, Calif., July 18, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, non-alcoholic steatohepatitis (NASH) and obesity, today announced it will host a virtual key opinion leader event to highlight the TERN-701 program and discuss advances in the treatment landscape for chronic myeloid leukemia (CML).
  • The event will be led by Emil Kuriakose, M.D., chief medical officer, oncology, at Terns and will feature presentations and discussion with:
    Event details are as follows:
    A webcast of the event will be available on the investor relations page of the Terns Pharmaceuticals website at http://ir.ternspharma.com .
  • A replay of the webcast will be archived on Terns’ website for at least 30 days following the presentation.

CCube Solutions appoints seasoned healthcare software business leader Alistair Eaton as CEO

Retrieved on: 
Tuesday, July 4, 2023
Vista Equity Partners, Software as a service, Health, Mental health, Tern, EDMS, Community, Acquisition, Education minister, R v Bournewood Community and Mental Health NHS Trust, Growth, NHS, Development, Management, Nursing

LONDON, July 4, 2023 /PRNewswire/ -- CCube Solutions, a leading provider of Electronic Document Management Systems (EDMS) to the NHS for over two decades, announces the appointment of Alistair Eaton as its new CEO.

Key Points: 
  • LONDON, July 4, 2023 /PRNewswire/ -- CCube Solutions, a leading provider of Electronic Document Management Systems (EDMS) to the NHS for over two decades, announces the appointment of Alistair Eaton as its new CEO.
  • Alistair is a proven health tech business leader with significant experience in scaling software businesses.
  • He has over 27 years of experience of selling mission-critical and complex enterprise software solutions to the NHS and the private healthcare care market.
  • Alistair Eaton said, "The adoption of modern public cloud technology in CCube's latest product offerings reinforces its status as an innovative pioneer in healthcare EDMS.

Terns Pharmaceuticals Highlights New Preclinical Data for TERN-601 Program in Obesity at the ADA’s 83rd Annual Scientific Session and Upcoming Events

Retrieved on: 
Monday, June 26, 2023
Obesity, Food, NASH, Clinical trial, Paracetamol, Piper Sandler Companies, Plasma, Blood, American Diabetes Association, Fireside, Fatty liver disease, Tern, Webcast, Mouse, APAP, ADA, Glucose tolerance test, Trapping, Pharmaceutical industry

FOSTER CITY, Calif., June 26, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, non-alcoholic steatohepatitis (NASH) and obesity, today announced that new preclinical data from a transgenic mouse model evaluating TERN-601, the Company’s novel oral GLP-1R agonist, were highlighted in a poster presentation at the American Diabetes Association’s 83rd Annual Scientific Sessions, which took place from June 23-26, 2023 in San Diego.

Key Points: 
  • Food intake was also recorded for 24 hours in fasted mice treated with TERN-601, with food available 15 minutes post dose.
  • Piper Sandler Inaugural Obesity Investor Day:
    The Piper Sandler event webcast link is available from Piper Sandler and will require registration.
  • A webcast of Terns’ obesity event will be available on the investor relations page of the Terns Pharmaceuticals website at http://ir.ternspharma.com.
  • A replay of the webcast will be archived on Terns’ website for at least 30 days following the presentation.

Terns Pharmaceuticals to Highlight New Preclinical Data for TERN-601 Program in Obesity at the American Diabetes Association’s 83rd Annual Scientific Sessions

Retrieved on: 
Monday, May 22, 2023
Fatty liver disease, Tern, Obesity, Type 2 diabetes, NASH, American Diabetes Association, Pharmaceutical industry

The abstract will also be published online on the journal Diabetes® website.

Key Points: 
  • The abstract will also be published online on the journal Diabetes® website.
  • “Obesity is a growing epidemic and GLP-1 agonists have demonstrated broad metabolic benefits in obesity and Type 2 diabetes in clinical trials.
  • Unfortunately, they are often limited by injectable dosing, poor tolerability and cost concerns.
  • All information is subject to embargo until Friday, June 23, 2023 at 6:30pm PT.

Terns Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Updates

Retrieved on: 
Monday, May 15, 2023
Obesity, NASH, CML, GIPR, American Society for Pharmacology and Experimental Therapeutics, CT1, Clinical trial, Pharmacokinetics, Hope, BCR-ABL, Experiment, Acute leukemia, Hansoh Pharmaceutical, MRI, Administration, Team Impulse, Fatty liver disease, Tern, Poster, Research and development, R, Pharmacology, Society, Safety, ASPET, Rare-earth element, Pharmaceutical industry, Medical imaging, Cryptocurrency

FOSTER CITY, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, non-alcoholic steatohepatitis (NASH) and obesity, today reported financial results for the first quarter ended March 31, 2023 and corporate updates.

Key Points: 
  • Based on its current operating plan, Terns expects these funds will be sufficient to support its planned operating expenses into 2026.
  • Research and Development (R&D) Expenses: R&D expenses were $17.1 million for the quarter ended March 31, 2023, as compared with $8.1 million for the quarter ended March 31, 2022.
  • General and Administrative (G&A) Expenses: G&A expenses were $7.1 million for the quarter ended March 31, 2023, as compared with $5.7 million for the quarter ended March 31, 2022.
  • Net Loss: Net loss was $21.5 million for the quarter ended March 31, 2023, as compared with $13.8 million for the quarter ended March 31, 2022.

Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates

Retrieved on: 
Monday, March 27, 2023
Fatty liver disease, Biotechnology, Acute leukemia, Common stock, Growth, DSM-IV codes, Research and development, Obesity, R, NASH, MD, Administration, CML, Pharmaceutical industry, Cryptocurrency, Tern

FOSTER CITY, Calif., March 27, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, non-alcoholic steatohepatitis (NASH) and obesity today reported financial results for the fourth quarter and full year ended December 31, 2022 and corporate updates.

Key Points: 
  • FOSTER CITY, Calif., March 27, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, non-alcoholic steatohepatitis (NASH) and obesity today reported financial results for the fourth quarter and full year ended December 31, 2022 and corporate updates.
  • We are fortunate to have a strong balance sheet to support development activities and the growth of our company into 2026,” said Mark Vignola, chief financial officer of Terns.
  • Based on its current operating plan, Terns expects these funds will be sufficient to support its planned operating expenses into 2026.
  • Common Stock and Pre-Funded Warrants: As of December 31, 2022, there were 53.7 million shares of common stock and 14.6 million pre-funded warrants issued and outstanding.